Table 5.

Adjusted associations between HIV specific factors and QTVI

HIV-Related Factors (N* = 510)	Beta-coefficient (95% CI)	P
Viral load
Undetectable (<20 copies/mL); N = 417 (82%)	Ref	Ref
Low (20–500 copies/mL); N = 60 (12%)	0.04 (−0.06,0.14)	0.40
High (>500 copies/mL); N = 33 (7%)	0.12 (0.00,0.24)	0.057
Current CD4+ T-Cell Count (cells/mL)
>400; N = 450 (89%)	Ref	Ref
≤400; N = 60 (11%)	0.05 (−0.05,0.14)	0.32
Nadir CD4+ T-Cell Count (cells/mL)
>400; N = 179 (35%)	Ref	Ref
≤400; N = 326 (65%)	−0.06 (−0.13, 0.00)	0.067
Clinical history of AIDS; N = 53 (10%)	0.12 (0.02, 0.22)	0.024
Duration of HAART use (per 10 years)	0.00 (−0.06, 0.05)	0.90
Current Protease Inhibitor Use	0.05 (−0.02, 0.12)	0.13

Beta-coefficients (95% confidence intervals (CI)) for associations with QTVI reported from mixed-effects linear regression models (similar to model B and C except for HIV serostatus) conducted among HIV+ subgroup.

^*Of 589 HIV+ men, 79 were missing at least one clinical variable used for adjustment and were excluded.